PLGA Nanoparticles for Ultrasound-Mediated Gene Delivery to Solid Tumors
Figure 10
Future Potential of PLGA-based nanoparticles for realizing efficient in vivo drug delivery. (a) PLGA formulations for drug delivery. The antitumor efficacy of single intratumoral injections of drugs or controls was compared for several NP groups. Groups examined included saline, pegylated PLGA NP (NP), Docatexel- (Dtxl-) encapsulated NP (Dtxl-NP) at 40 mg/kg, or Dtxl-NP-PSMA targeted Aptamer conjugates at 40 mg/kg (Dtxl-NP-Apt). Aptamer-targeted NPs were more efficacious in tumor reduction compared to control groups. Data points labeled with “*” were statistically significant compared with all other groups by analysis of variance (ANOVA) at a 95% confidence interval. (b) Representative mice at the end point for each group are shown (left) alongside images of excised tumors (right). For the Dtxl-NP-Apt group, which achieved complete tumor regression, the scar tissue and underlying skin at the site of injection are shown. Black arrows point to the position of the implanted tumor on each mouse. Reprinted from [68] with permission from PNAS.
